Ultraviolet A1 phototherapy for mycosis fungoides.
BACKGROUND
Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, and is characterized by a malignant proliferation of CD4+ cells. Psoralen ultraviolet A (PUVA) irradiation is the most common treatment for cutaneous lesions. However, PUVA carries the risk of adverse reactions to psoralens and long-term risk of skin cancer. UVA1 may be a safer alternative.


OBJECTIVE
To assess the efficacy of UVA1 phototherapy in patients with early-stage MF (T1-T2).


METHODS
Four patients with early-stage MF were treated with 1630-2710 J/cm(2) UVA1 given in 29-40 fractions, and the effect was assessed by clinical examination and by high-resolution ultrasonography.


RESULTS
Complete clinical remission of MF was achieved in all cases.


CONCLUSIONS
This preliminary report indicates that UVA1 phototherapy might be an efficient treatment for early-stage MF.
Department of Dermatology, Poznan Medical University of Sciences, Poznan, Poland.
K
K
Olek-Hrab
W
W
Silny
A
A
Dańczak-Pazdrowska
A
A
Osmola-Mańkowska
P A
PA
Sadowska
A
A
Polańska
R
R
Gniadecki
D
D
Jenerowicz
D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000532:radiotherapy*; D014467:Ultraviolet Therapy / Q000379:methods*